PortfoliosLab logoPortfoliosLab logo

Tema Obesity & Cardiometabolic ETF (HRTS) Alternatives

Tema Obesity & Cardiometabolic ETF (HRTS) belongs to the Health & Biotech Equities category. Below you'll find alternative ETFs from the same category, ranked by key criteria, plus funds that investors commonly compare with HRTS. Use the tables to find lower-cost options, better risk-adjusted returns, or funds that fit a different role in your portfolio.

Cheapest Alternatives to HRTS

HRTS charges 0.75% annually. Among ETFs in the Health & Biotech Equities category, these options have the lowest expense ratios among HRTS alternatives.


Best Risk-Adjusted Alternatives to HRTS

Among ETFs in the Health & Biotech Equities category, these options rank highest on PortfoliosLab's risk-adjusted score, which accounts for volatility, drawdown, and return consistency over a 1-year period.


Top Performing HRTS Alternatives (YTD)

HRTS alternatives from the Health & Biotech Equities category, sorted by year-to-date return.


Lowest Volatility Alternatives to HRTS

HRTS alternatives from the Health & Biotech Equities category, sorted by annualized volatility over the past year.


Lowest Drawdown Alternatives to HRTS

HRTS alternatives from the Health & Biotech Equities category, sorted by maximum drawdown over the past year.


Other ETFs from Tema

Most popular Tema ETFs on PortfoliosLab, across asset classes.


Often Compared With HRTS

What investors most often compare with HRTS, based on PortfoliosLab usage data.


Compare HRTS with Any Fund or Stock

Compare HRTS with any ETF, mutual fund, or stock using PortfoliosLab's comparison tool.